Nascent Biotech, Inc. announced the completion of the Fourth Cohort in dosing patients in the Company's Phase I trial to evaluate Pritumumab ("PTB") as a treatment for Brain Cancer, including Primary and metastatic Brain Tumors. After reviewing data gathered from the four completed cohorts, this milestone will allow the trial to advance to a fifth and final cohort. Patient enrollment continues for Phase I. Following completion of dosing of the Fifth Cohort, the Phase I trial will be complete, and the Company will prepare data for submission to the FDA in preparation for Phase 2 clinical research.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.076 USD | -14.61% |
|
-10.59% | -56.04% |
Jul. 01 | Nascent Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
Apr. 16 | Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing Run | CI |
1st Jan change | Capi. | |
---|---|---|
-56.04% | 15.33M | |
+20.88% | 127B | |
+23.22% | 116B | |
+25.15% | 27.69B | |
-19.11% | 19.62B | |
-16.57% | 16.26B | |
-15.88% | 15.49B | |
+11.41% | 14.81B | |
-46.65% | 14.39B | |
+56.67% | 14.11B |
- Stock Market
- Equities
- NBIO Stock
- News Nascent Biotech, Inc.
- Nascent Biotech, Inc. Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer